Pancreatitis from GLP-1 Medications in Illinois
Last Updated: April 1, 2026
Pancreatitis cases linked to GLP-1 medications are being filed by Illinois residents. Illinois is one of the most important jurisdictions for pharmaceutical litigation in the United States, with the Northern District in Chicago handling a massive caseload that includes multi-district drug injury cases. The state's 12.5 million residents and world-class medical institutions mean substantial numbers of people have been prescribed Depo-Provera and GLP-1 medications. Illinois applies a two-year statute of limitations with a discovery rule, and its courts have a well-developed body of product liability law.
Pancreatitis has been linked to GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity. Illinois residents who developed pancreatitis after using these drugs may qualify for compensation. The product liability statute of limitations in Illinois is 2 years. Cases are pending in federal MDL, and attorneys handle claims on a contingency fee basis — no cost unless you win.
Pancreatitis and GLP-1 Medications
Pancreatitis is an inflammation of the pancreas that causes severe, often debilitating abdominal pain. For Illinois residents who developed pancreatitis after using GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity, the condition can range from acute episodes requiring emergency hospitalization to chronic pancreatitis causing permanent organ damage. Acute pancreatitis can be life-threatening, with complications including pancreatic necrosis, organ failure, and sepsis. Even patients who recover from acute episodes may face recurring attacks, dietary restrictions, and long-term digestive problems.
The manufacturers of these medications — Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Mounjaro and Trulicity) — are accused of failing to adequately warn patients and prescribing physicians about the risk of pancreatitis. Despite internal data and emerging clinical evidence suggesting a causal link, the drug labels did not include sufficient warnings about the severity and potential permanence of this condition.
For Illinois residents, this means that if you developed pancreatitis while taking a GLP-1 medication, you may have a valid product liability claim. The federal multidistrict litigation (MDL 3094) is consolidating these cases for efficient pretrial proceedings, while preserving each plaintiff's individual right to trial.
Recognizing Pancreatitis from GLP-1 Drugs
If you are a Illinois resident who used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity and experienced any of the following symptoms, you may have developed pancreatitis as a result:
Severe upper abdominal pain
Pain radiating to the back
Nausea and vomiting
Fever
Rapid pulse
Diagnosis
Pancreatitis is typically confirmed through blood tests (lipase/amylase levels) and imaging (ct scan or ultrasound). If you are experiencing symptoms but have not yet received a formal diagnosis, an attorney can help coordinate appropriate medical evaluation as part of your case. Having documented medical evidence strengthens your claim significantly.
Filing a Pancreatitis Claim in Illinois
Illinois residents who developed pancreatitis after using GLP-1 medications have specific legal options and deadlines. The statute of limitations for product liability claims in Illinois is 2 years, and the personal injury statute of limitations is 2 years.
Importantly, Illinois recognizes the discovery rule. This means the statute of limitations clock may not start until you knew or reasonably should have known that your pancreatitis was caused by a GLP-1 medication. Given that the scientific understanding of the link between these drugs and pancreatitis has evolved significantly in recent years, many Illinois residents may still be within their filing window even if their injury occurred some time ago.
Cases may be filed in the Illinois Circuit Courts at the state level or in federal court through the Northern District of Illinois (or other Illinois federal districts). Most GLP-1 injury cases are being coordinated through the federal MDL for pretrial proceedings.
Illinois legal landscape: Illinois applies modified comparative fault with a 50% bar. The state follows strict liability for product defect claims under a framework influenced by the Restatement (Second) of Torts, and it recognizes the learned intermediary doctrine for prescription drug failure-to-warn claims. Residents in Chicago, Aurora, Naperville, Rockford, and Springfield and surrounding areas should consult with an attorney to evaluate their potential pancreatitis claim.
Personal Injury SOL
2 years
Product Liability SOL
2 years
Discovery Rule
Yes
GLP-1 Drugs Linked to Pancreatitis
The following GLP-1 receptor agonist medications have been linked to pancreatitis in ongoing litigation. If you used any of these drugs in Illinois and developed pancreatitis, you may qualify for a claim:
Ozempic
Semaglutide injection by Novo Nordisk. Prescribed for type 2 diabetes.
Wegovy
Semaglutide injection by Novo Nordisk. Prescribed for weight management.
Mounjaro
Tirzepatide injection by Eli Lilly. Prescribed for type 2 diabetes and weight management.
Rybelsus
Oral semaglutide by Novo Nordisk. Prescribed for type 2 diabetes.
Saxenda
Liraglutide injection by Novo Nordisk. Prescribed for weight management.
Trulicity
Dulaglutide injection by Eli Lilly. Prescribed for type 2 diabetes.
Do You Qualify for a Pancreatitis Claim in Illinois?
Illinois residents may be eligible to file a pancreatitis claim if the following criteria apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity or another GLP-1 receptor agonist medication.
Diagnosed with Pancreatitis
You received a medical diagnosis of pancreatitis through blood tests (lipase/amylase levels) and imaging (ct scan or ultrasound).
Injury Occurred After Drug Use
Your pancreatitis developed after you began taking the GLP-1 medication, establishing a timeline consistent with causation.
Within Illinois's Filing Deadline
Your claim falls within Illinois's product liability statute of limitations (2 years). The discovery rule may extend this deadline. An attorney can evaluate your specific timeline.
Pancreatitis in Illinois: FAQ
What is pancreatitis and how is it linked to GLP-1 medications in Illinois?
Inflammation of the pancreas causing severe abdominal pain. GLP-1 medications including Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, Trulicity have been linked to an increased risk of developing this condition. Illinois residents who were prescribed these medications and subsequently developed pancreatitis may be eligible to file a lawsuit seeking compensation for their injuries, medical expenses, and other damages.
What are the symptoms of pancreatitis caused by Ozempic or other GLP-1 drugs?
Common symptoms of pancreatitis include severe upper abdominal pain, pain radiating to the back, nausea and vomiting, fever, rapid pulse. If you experienced these symptoms after taking Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity in Illinois, you should seek medical attention immediately and consider having your case evaluated for potential legal action.
How is pancreatitis diagnosed for purposes of a GLP-1 lawsuit?
Pancreatitis is typically diagnosed through blood tests (lipase/amylase levels) and imaging (ct scan or ultrasound). For Illinois residents filing a GLP-1 injury claim, medical documentation confirming your diagnosis is important for establishing your case. If you have not yet been formally diagnosed but are experiencing symptoms, your attorney can help coordinate appropriate medical evaluation.
What is the statute of limitations for a pancreatitis claim in Illinois?
In Illinois, the statute of limitations for product liability claims is 2 years. Illinois recognizes the discovery rule, meaning the filing deadline may start from when you discovered or should have discovered that your pancreatitis was caused by a GLP-1 medication. Consult with an attorney to determine your exact deadline.
What compensation can I receive for pancreatitis caused by GLP-1 drugs in Illinois?
Illinois residents who qualify may recover compensation for medical expenses (including emergency treatment, surgery, hospitalization, and rehabilitation), lost wages, pain and suffering, emotional distress, and diminished quality of life. The amount depends on the severity of your pancreatitis and its impact on your daily life.
Is there any cost to file a pancreatitis claim in Illinois?
There is no upfront cost. Attorneys handling GLP-1 pancreatitis cases in Illinois work on a contingency fee basis, meaning they only receive payment if you receive compensation through settlement or trial verdict. NuLegal's initial case review is completely free with no obligation.
Related Resources
Other GLP-1 Injuries in Illinois
Illinois Residents: Get Your Free Case Review
If you developed pancreatitis after using Ozempic, Wegovy, Mounjaro, Rybelsus, Saxenda, or Trulicity, time may be limited. Illinois's product liability statute of limitations is 2 years. Get a free, no-obligation evaluation today.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.